{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:41:18Z","timestamp":1787622078665,"version":"build-2736575974"},"reference-count":37,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Vitiligo is a chronic skin disease resulting in destruction of melanocytes and loss of pigmentation. Little is known about epidemiology and comorbidity in Germany. This retrospective cohort analysis used nationwide statutory health insurance data (2016 to 2020). Disease rates were calculated using varying case definitions. Comorbidity was assessed against 3 control groups: persons without vitiligo, with atopic dermatitis, and with psoriasis (1:3 propensity score matching). In 2020, 4,631 persons were diagnosed with vitiligo in DAK-Gesundheit (DAK-G, mean age 56.93 years, ~148,437) and 5,820 persons in the German Analysis Database for Evaluation and Health Services Research (~144,855). Prevalence ranged from 0.12% (confidence interval [CI] 0.12\u20130.12) to 0.20% (CI 0.19\u20130.20), and incidence from 0.04% (CI 0.03\u20130.04) to 0.06% (CI 0.06\u20130.06). Rates increased with age. Women (mean age 58.60 years) were more frequently affected. Vitiligo was associated with alopecia areata (relative risk 7.14, CI 4.63\u201311.00) and systemic sclerosis (relative risk 3.20, CI 1.58\u20136.47). Several mental illnesses (depression: relative risk\u2009=\u20091.23, CI 1.15\u20131.32, anxiety: relative risk\u2009=\u20091.32, CI 1.19\u20131.47), were linked to skin diseases like vitiligo, atopic dermatitis, or psoriasis. Vitiligo affects a notable proportion of the population, with detected comorbidities supporting prior findings. To ensure reliable results, claims data should be validated through primary data linkage or sensitivity testing.<\/jats:p>","DOI":"10.2340\/actadv.v106.44468","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:12:42Z","timestamp":1777439562000},"page":"adv44468","source":"Crossref","is-referenced-by-count":1,"title":["Epidemiology and Comorbidity of Vitiligo in Germany: A Claims Data Analysis"],"prefix":"10.2340","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0760-3103","authenticated-orcid":false,"given":"Theresa","family":"Klinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8728","authenticated-orcid":false,"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Baumeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Grellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Kamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7338-7734","authenticated-orcid":false,"given":"Markus","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2676-1479","authenticated-orcid":false,"given":"Kristina","family":"Hagenstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"153383","doi-asserted-by":"crossref","unstructured":"Ta\u00efeb A, Picardo M. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007; 20: 27\u201335.","DOI":"10.1111\/j.1600-0749.2006.00355.x"},{"key":"153384","doi-asserted-by":"crossref","unstructured":"Kr\u00fcger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children\/adolescents and adults. Int J Dermatol 2012; 51: 1206\u20131212. 1206\u20131212.","DOI":"10.1111\/j.1365-4632.2011.05377.x"},{"key":"153385","doi-asserted-by":"crossref","unstructured":"Haulrig MB, Al-Sofi R, Baskaran S, Bergmann MS, L\u00f8vendorf M, Dyring-Andersen B, et al. The global epidemiology of vitiligo: a systematic review and meta-analysis of the incidence and prevalence. JEADV Clin Pract 2024; 3: 1410\u20131419.","DOI":"10.1002\/jvc2.526"},{"key":"153386","doi-asserted-by":"crossref","unstructured":"Zhang Y, Cai Y, Shi M, Jiang S, Cui S, Wu Y, et al. The prevalence of vitiligo: a meta-analysis. PloS One 2016; 11: e0163806.","DOI":"10.1371\/journal.pone.0163806"},{"key":"153387","doi-asserted-by":"crossref","unstructured":"Mohr N, Petersen J, Kirsten N, Augustin M. Epidemiology of vitiligo: a dual population-based approach. Clin Epidemiol 2021; 13: 373\u2013382.","DOI":"10.2147\/CLEP.S304155"},{"key":"153388","doi-asserted-by":"crossref","unstructured":"Abbas S, Ihle P, K\u00f6ster I, Schubert I. Estimation of disease incidence in claims data dependent on the length of follow-up: a methodological approach. Health Serv Res 2012; 47: 746\u2013755.","DOI":"10.1111\/j.1475-6773.2011.01325.x"},{"key":"153389","doi-asserted-by":"crossref","unstructured":"Tang L, Li F, Xu F, Yan S, Zhou J, Li J, et al. Prevalence of vitiligo and associated comorbidities in adults in Shanghai, China: a community-based, cross-sectional survey. Ann Palliat Med 2021; 10: 8103\u20138111.","DOI":"10.21037\/apm-21-1738"},{"key":"153390","doi-asserted-by":"crossref","unstructured":"Li C-Y, Dai Y-X, Chen Y-J, Chu S-Y, Chen T-J, Wu C-Y, et al. Cancer risks in vitiligo patients: a nationwide population-based study in Taiwan. Int J Environ Res Public Health 2018; 15.","DOI":"10.3390\/ijerph15091847"},{"key":"153391","doi-asserted-by":"crossref","unstructured":"Morrison B, Burden-Teh E, Batchelor JM, Mead E, Grindlay D, Ratib S. Quality of life in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol 2017; 177: e338\u2013e339.","DOI":"10.1111\/bjd.15933"},{"key":"153392","doi-asserted-by":"crossref","unstructured":"Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis. J Eur Acad Dermatol Venereol 2018; 32: 1343\u20131351.","DOI":"10.1111\/jdv.14739"},{"key":"153393","doi-asserted-by":"crossref","unstructured":"Kussainova A, Kassym L, Akhmetova A, Glushkova N, Sabirov U, Adilgozhina S, et al. Vitiligo and anxiety: a systematic review and meta-analysis. PloS One 2020; 15: e0241445.","DOI":"10.1371\/journal.pone.0241445"},{"key":"153394","doi-asserted-by":"crossref","unstructured":"Ezzedine K, Eleftheriadou V, Jones H, Bibeau K, Kuo FI, Sturm D, et al. Psychosocial effects of vitiligo: a systematic literature review. Am J Clin Dermatol 2021; 22: 757\u2013774.","DOI":"10.1007\/s40257-021-00631-6"},{"key":"153395","doi-asserted-by":"crossref","unstructured":"Fabrazzo M, Cipolla S, Signoriello S, Camerlengo A, Calabrese G, Giordano GM, et al. A systematic review on shared biological mechanisms of depression and anxiety in comorbidity with psoriasis, atopic dermatitis, and hidradenitis suppurativa. Eur Psychiatry 2021; 64: e71.","DOI":"10.1192\/j.eurpsy.2021.2249"},{"key":"153396","doi-asserted-by":"crossref","unstructured":"Wilson EB. On confidence intervals. Proc Natl Acad Sci U S A 1942; 28: 88\u201393.","DOI":"10.1073\/pnas.28.3.88"},{"key":"153397","doi-asserted-by":"crossref","unstructured":"Tsadik AG, Legesse GF, Desta DM, Assefa BT, Kidanemariam HG, Gidey MT. Clinico-epidemiological profile and treatment pattern of vitiligo in selected dermatological clinics of Mekelle City, Northern Ethiopia. Dermatol Res Pract 2020; 2020: 3625753.","DOI":"10.1155\/2020\/3625753"},{"key":"153398","doi-asserted-by":"crossref","unstructured":"Gandhi K, Ezzedine K, Anastassopoulos KP, Patel R, Sikirica V, Daniel SR, et al. Prevalence of vitiligo among adults in the United States. JAMA Dermatol 2022; 158: 43\u201350.","DOI":"10.1001\/jamadermatol.2021.4724"},{"key":"153399","doi-asserted-by":"crossref","unstructured":"Radtke MA, Sch\u00e4fer I, Gajur AI, Augustin M. Clinical features and treatment outcomes of vitiligo from the patients\u2019 perspective: results of a national survey in Germany. Dermatology (Basel, Switzerland) 2010; 220: 194\u2013200.","DOI":"10.1159\/000275657"},{"key":"153400","doi-asserted-by":"crossref","unstructured":"Migayron L, Boniface K, Seneschal J. Vitiligo, from physiopathology to emerging treatments: a review. Dermatol Ther (Heidelb) 2020; 10: 1185\u20131198.","DOI":"10.1007\/s13555-020-00447-y"},{"key":"153401","doi-asserted-by":"crossref","unstructured":"Schubert I, Ihle P, K\u00f6ster I. Interne Validierung von Diagnosen in GKV-Routinedaten: Konzeption mit Beispielen und Falldefinition. Gesundheitswesen 2010; 72: 316\u2013322.","DOI":"10.1055\/s-0030-1249688"},{"key":"153402","doi-asserted-by":"crossref","unstructured":"Radtke MA, Sch\u00e4fer I, Gajur A, Langenbruch A, Augustin M. Willingness-to-pay and quality of life in patients with vitiligo. Br J Dermatol 2009; 161: 134\u2013139.","DOI":"10.1111\/j.1365-2133.2009.09091.x"},{"key":"153403","doi-asserted-by":"crossref","unstructured":"Augustin M, Gajur AI, Reich C, Rustenbach SJ, Schaefer I. Benefit evaluation in vitiligo treatment: development and validation of a patient-defined outcome questionnaire. Dermatology (Basel) 2008; 217: 101\u2013106.","DOI":"10.1159\/000128992"},{"key":"153404","doi-asserted-by":"crossref","unstructured":"Choi CW, Eun SH, Choi KH, Bae JM. Increased risk of comorbid rheumatic disorders in vitiligo patients: a nationwide population-based study. J Dermatol 2017; 44: 909\u2013913.","DOI":"10.1111\/1346-8138.13846"},{"key":"153405","doi-asserted-by":"crossref","unstructured":"Dsouza PA, Monteiro RC, Dias M, Prabhu SH, Bhat RM, Jayaraman J, et al. Beyond the surface: decoding pityriasis versicolor through clinical, dermoscopic and microbiological exploration. Indian J Dermatol 2025; 70: 6\u201310.","DOI":"10.4103\/ijd.ijd_391_24"},{"key":"153406","doi-asserted-by":"crossref","unstructured":"Leung DYM. New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergol Int2013; 62: 151\u2013161.","DOI":"10.2332\/allergolint.13-RAI-0564"},{"key":"153407","doi-asserted-by":"crossref","unstructured":"Li X, Kong L, Li F, Chen C, Xu R, Wang H, et al. Association between psoriasis and chronic obstructive pulmonary disease: a systematic review and meta-analysis. PloS One 2015; 10: e0145221.","DOI":"10.1371\/journal.pone.0145221"},{"key":"153408","doi-asserted-by":"crossref","unstructured":"Klinger T, Augustin M, Leicht G, Moritz S, Hagenstr\u00f6m K. Prevalence and comparative risk of mental health disorders in persons with vitiligo: a retrospective matched cohort study using claims data with expert-informed case validation. BMJ Open 2026; 16: e106687.","DOI":"10.1136\/bmjopen-2025-106687"},{"key":"153409","doi-asserted-by":"crossref","unstructured":"Montgomery SN, Syder N, Barajas G, Elbuluk N. Psychological comorbidities of vitiligo: a retrospective cross-sectional analysis in an urban population. Arch Dermatol Res 2023; 316: 14.","DOI":"10.1007\/s00403-023-02771-7"},{"key":"153410","doi-asserted-by":"crossref","unstructured":"Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41\u201355.","DOI":"10.1093\/biomet\/70.1.41"},{"key":"153411","doi-asserted-by":"crossref","unstructured":"Mei H, Xu Y, Wang J, Ma S. Evaluation of survival outcomes of endovascular versus open aortic repair for abdominal aortic aneurysms with a big data approach. Entropy (Basel) 2020; 22.","DOI":"10.3390\/e22121349"},{"key":"153412","doi-asserted-by":"crossref","unstructured":"Wang C, Chen M-H, Schifano E, Wu J, Yan J. Statistical methods and computing for big data. Stat Interface 2016; 9: 399\u2013414.","DOI":"10.4310\/SII.2016.v9.n4.a1"},{"key":"153413","unstructured":"Wagner C. Die Population unter Risiko bei Pr\u00e4valenz- und Inzidenzsch\u00e4tzungen \u2013 Nennerkonzepte. In: Routinedaten im Gesundheitswesen: Handbuch Sekund\u00e4rdatenanalyse: Grundlagen, Methoden und Perspektiven. Bern: Hans Huber; 2014: p. 424\u2013432."},{"key":"153414","doi-asserted-by":"crossref","unstructured":"Swart E, Gothe H, Geyer S, Jaunzeme J, Maier B, Grobe TG, et al. Gute Praxis Sekund\u00e4rdatenanalyse (GPS): Leitlinien und Empfehlungen. Gesundheitswesen 2015; 77: 120\u2013126.","DOI":"10.1055\/s-0034-1396815"},{"key":"153415","doi-asserted-by":"crossref","unstructured":"Hagenstr\u00f6m K, Protz K, Petersen J, Augustin M. Development of a model to predict closure of chronic wounds in Germany: claims data analysis. Int Wound J 2022; 19: 76\u201385.","DOI":"10.1111\/iwj.13599"},{"key":"153416","doi-asserted-by":"crossref","unstructured":"Busse R, Bl\u00fcmel M, Knieps F, B\u00e4rnighausen T. Statutory health insurance in Germany: a health system shaped by 135 years of solidarity, self-governance, and competition. Lancet 2017; 390: 882\u2013897.","DOI":"10.1016\/S0140-6736(17)31280-1"},{"key":"153417","doi-asserted-by":"crossref","unstructured":"Swart E, editor. Health care utilization research using secondary data. New York: Springer; 2014.","DOI":"10.1007\/978-1-4614-9191-0_5"},{"key":"153418","doi-asserted-by":"crossref","unstructured":"Swart E, Schmitt J. Standardized Reporting Of Secondary data Analyses (STROSA) \u2013 Vorschlag f\u00fcr ein Berichtsformat f\u00fcr Sekund\u00e4rdatenanalysen. Z Evid Fortbild Qual Gesundhwes 2014; 108: 511\u2013516.","DOI":"10.1016\/j.zefq.2014.08.022"},{"key":"153419","unstructured":"Arbeitsgruppe Epidemiologische Methoden der Deutschen Arbeitsgemeinschaft f\u00fcr Epidemiologie (DAE). Leitlinien und Empfehlungen \u2013 Deutsche Gesellschaft f\u00fcr Epidemiologie; 2023 [cited 2023 Oct 19]. Available from: https:\/\/www.dgepi.de\/de\/berichte-und-publikationen\/leitlinien-und-empfehlungen\/"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/44468\/53736","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/44468\/53736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:13:11Z","timestamp":1777439591000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/44468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":37,"URL":"https:\/\/doi.org\/10.2340\/actadv.v106.44468","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,29]]}}}